Skip to main content

Table 1 Baseline and clinical characteristics of HC and PD participants

From: Parkinson's disease peripheral immune biomarker profile: a multicentre, cross-sectional and longitudinal study

Characteristics

Discovery cohort

Validation cohort

Pa

Pb

PDa (N = 76)

HCb (N = 76)

p

PDa (N = 80)

HCb (N = 80)

p

Age (years)

62.2 ± 7.5

60.2 ± 8.2

0.14

63.7 ± 8.5

64.9 ± 8.8

0.40

0.25

0.01

Sex, N

        

 Female

38

28

0.14

44

39

0.43

0.63

0.15

 Male

38

48

 

36

41

   

Disease duration (years)

4.9 ± 4.3

/

 

3.6 ± 3.6

/

   

UPDRS I

8.0 ± 6.1

/

/

6.2 ± 4.5

/

/

0.05

/

UPDRS II

11.5 ± 6.8

/

/

12.7 ± 6.9

/

/

0.28

/

UPDRS III

28.4 ± 15.1

/

/

35.4 ± 18

/

/

0.01

/

  1. Data are expressed as mean and standard deviation (SD), as appropriate
  2. Pa: comparation of PD participants between discovery and validation cohort; Pb: comparation of HC participants between discovery and validation cohort
  3. PD Parkinson’s disease, UPDRS Unified Parkinson's Disease Rating Scale